Last reviewed · How we verify
Glucophage 1000 mg
At a glance
| Generic name | Glucophage 1000 mg |
|---|---|
| Sponsor | Sandoz |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Musculoskeletal
- Infections
- Nervous system
- General Disorders
- Gastrointestinal Disorders
- Injury
- Respiratory
- Skin
- Eye Disorders
- Psychiatric
- Investigations
- Renal
Key clinical trials
- Diabetes Management for Primary Healthcare Centers. (NA)
- Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function (PHASE2)
- An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer (PHASE2)
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients (PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma (PHASE2)
- Metformin Safety and Efficacy in Osteoarthritis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucophage 1000 mg CI brief — competitive landscape report
- Glucophage 1000 mg updates RSS · CI watch RSS
- Sandoz portfolio CI